Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma

There is a knowledge gap in understanding mechanisms of resistance to fibroblast growth factor receptor (FGFR) inhibitors (FGFRi) and a need for novel therapeutic strategies to overcome it. We investigated mechanisms of acquired resistance to FGFRi in patients with FGFR2-fusion-positive cholangiocar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2024-02, Vol.80 (2), p.322-334
Hauptverfasser:	DiPeri, Timothy P., Zhao, Ming, Evans, Kurt W., Varadarajan, Kaushik, Moss, Tyler, Scott, Stephen, Kahle, Michael P., Byrnes, Charnel C., Chen, Huiqin, Lee, Sunyoung S., Halim, Abdel-Baset, Hirai, Hiroshi, Wacheck, Volker, Kwong, Lawrence N., Rodon, Jordi, Javle, Milind, Meric-Bernstam, Funda
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Bile Duct Neoplasms - drug therapy Bile Duct Neoplasms - genetics Bile Duct Neoplasms - metabolism Bile Ducts, Intrahepatic - pathology biliary tract cancer Cholangiocarcinoma - drug therapy Cholangiocarcinoma - genetics Cholangiocarcinoma - metabolism combination therapies fibroblast growth factor receptor Humans Mitogen-Activated Protein Kinases - metabolism Mutation Precision oncology Protein Kinase Inhibitors - adverse effects Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism Proto-Oncogene Proteins B-raf - therapeutic use Proto-Oncogene Proteins p21(ras) - genetics Proto-Oncogene Proteins p21(ras) - metabolism Proto-Oncogene Proteins p21(ras) - therapeutic use Receptor, Fibroblast Growth Factor, Type 2 - genetics Receptor, Fibroblast Growth Factor, Type 2 - metabolism Retrospective Studies targeted therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!